GLENMARK PHARMACEUTICALS Q2 FY26 : CONS 💰 Net Profit: ₹610 Cr ⬆ 72% YoY, ⬆ 1203% QoQ 📉 Revenue: ₹6046 Cr ⬆ 76% YoY, ⬆ 85% QoQ ✅ EBITDA: ₹2359.6 Cr ⬆ 292% YoY, ⬆ 307% QoQ 📊 Margins: 39.03% vs 17.52% YoY, 39.03% vs 17.77% Qo